

#2

JC903 U.S. PTO
09/835759
04/16/01



"Express Mail" mailing label
Number EL497108984US

Date of Deposit 16 April 2001

I hereby Certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

M. Bud Nelson
Name M. Bud Nelson
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Barberá-Guillem

Filed: April 2001

For: Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Assistant Commissioner of Patents
Washington, D.C. 20231

Applicant wishes to make of record the following references under the provisions of 37 CFR 1.97 and to provide copies of relevant background cited in the application. The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application, or is to be considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove any document as a cited reference against the claims of the present invention.

References Cited

Please see attached Form PTO-1149 for list of publications, legible copies of all publication listed are enclosed.

Statement of Relevancy

1. U.S. Patent No. 4,578,269 to Morein. This patent discloses an immunogenic complex with triterpensaponin via use of a solubilizing agent.
2. U.S. Patent No. 4,877,611 to Cantrell. This patent discloses a vaccine with tumor-associated antigen, a endotoxin stimulant, a microbial-derived biological immunostimulant, and a pharmaceutically acceptable carrier.
3. U.S. Patent No. 5,709,860 to Raychaudhuri & Rastetter. This patent discloses a composition containing an antigen, detergent,

micelle-forming agent, and an oil.

4. U.S. Patent No. 4,724,213 to Epstein. This patent discloses hybridoma Lym-1.

5. U.S. Patent No. 5,593,676 to Bhat. This patent discloses methods of killing B cells using antibodies which bind CDIM.

6. U.S. Patent No. 5,843,439 to Anderson et al. This patent describes a method for treating B cell lymphoma using a radiolabeled chimeric anti-CD20 antibody.

7. U.S. Patent No. 5,736,137 to Anderson et al. This patent describes a chimeric anti-CD20 antibody.

8. U.S. Patent No. 5,776,456 to Anderson et al. This patent describes a method for treating B cell lymphoma using a chimeric anti-CD20 antibody.

9. U.S. Patent No. 5,789,554 to Leung & Hansen. This patent describes a method and composition for treating B cell lymphoma or leukemia using a humanized LL2 (anti-CD22) antibody.

10. U.S. Patent No. 6,183,744 to Goldenberg. This patent describes a method and composition for treating B cell lymphoma or leukemia using anti-CD22 antibody.

11. U.S. Patent No. 6,187,287 to Leung & Hansen. This patent describes a method and composition for treating B cell lymphoma or leukemia using a humanized LL2 (anti-CD22) antibody.

12. Monzavi-Karbassi & Kieber-Emmons. *BioTechniques* 30:170-189, January 2001. This publication reviews current concepts in cancer vaccine strategies.


13. Herlyn & Birebent. *Ann. Med.* 31:66-78, 1999. This publication reviews current concepts in cancer vaccine development.

14. CancerNet.nci.nih.gov. This publication discloses current vaccine trials for cancer as compiled by the National Cancer Institute.

The person making this statement is the patent attorney who signs below on the basis of the information supplied by the inventors, and as the attorney associated with the filing and prosecution of this application (37 CFR 1.56(a)):

BioCrystal Ltd.
575 McCorkle Blvd
Westerville, OH 43082-8888

Date: 16 April 2001



M. Bud Nelson
Reg. No. 35,300

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

Application Number

Applicant(s)

Filing Date

16 April 2001

Group Art Unit

04/16/01
0035759
S-U-0035759
04/16/01

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,578,269	03/25/1986	Morein			
		4,877,611	10/31/1989	Cantrell			
		5,709,860	01/20/1998	Raychaudhuri & Rastetter			
		4,724,213	02/09/1998	Epstein			
		5,593,676	01/14/1997	Bhat			
		5,843,439	12/01/1998	Anderson et al.			
		5,736,137	04/07/1998	Anderson et al.			
		5,776,456	07/07/1998	Anderson et al.			
		5,789,554	08/04/1998	Leung & Hansen			
		6,183,744	02/06/2001	Goldenberg			
		6,187,287	02/13/2001	Leung & Hansen			

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	Behjatolah Monzavi-Karbassi & Kieber-Emmons. "Current Concepts in Cancer Vaccine Strategies", BioTechniques, vol. 30, pages 170-189, January 2001
	Herlyn & Birebent. "Advances in cancer vaccine development", Ann. Med., vol. 31, pages 66-78, 1999.
	Clinical trials - cancer, vaccine therapy. Cancernet.nci.nih.gov. 04/09/2001

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.